Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study
Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.
Summary
Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
Official title: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2027-01
Completion Date
2029-10
Last Updated
2026-11-16
Healthy Volunteers
No
Interventions
Injecting KL002 into the bilateral putamen
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes
Locations (1)
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China